Web Desc
The Modes of Action of Vaccine Adjuvants
Organizer(s): Philippa C. Marrack, Steven Reed and Robert A. Seder
Date: October 08 - 13, 2014
Location: Sheraton Seattle Hotel, Seattle, WA, USA
Sponsored by Pfizer Inc. Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation.
Summary of Meeting:
Globally, vaccines are the most effective medical interventions in limiting morbidity and mortality against infections. Effective vaccines are administered in a variety of formulations and include not only portions of their target but also adjuvants. Adjuvants can improve the magnitude and breadth of the immune response and immunological memory against the target and also determine the nature of the generated immune response. Almost all vaccines that are now in use include adjuvants, such as nucleic acids from the target organisms, in the case of attenuated virus vaccines, insoluble aluminum salts (alum), oil-in-water emulsions (MF-59) or formulated toll-like receptor ligands (MPL-TLR4). However, the world still lacks consistently effective vaccines against many infectious agents, tuberculosis, malaria and HIV and against cancers. Therefore much current research is devoted to identification of newer adjuvants, adjuvants that will safely induce the type of immune response that will most effectively deal with its target. In many cases the precise mode of action of the adjuvant is not known. For example the mode of action of alum, an adjuvant that has been used in vaccines since the 1930s and generates excellent antibody responses, is still inadequately understood. This conference will focus on the cell and molecular mechanisms of action of old and new adjuvants and other immunomodulatory agents and their use in various vaccines against infectious diseases and cancer.
Global Health Travel Award Deadline: May 6 2014
Scholarship Deadline: June 10 2014
Discounted Abstract Deadline: June 10 2014
Abstract Deadline: July 8 2014
Discounted Registration Deadline: August 7 2014
Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting:
Bill & Melinda Gates FoundationPfizer Inc.
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

CSL Limited

Dynavax Technologies Corporation

Novartis Vaccines and Diagnostics
We gratefully acknowledge the generous grant for this conference provided by:

National Institute of Allergy and Infectious Diseases (NIAID)
Grant No. 1R13AI114173-01
The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

Program

Wednesday, October 08 | 2:00PM - 7:30PM
Keystone Symposia: Arrival and Registration
Room: Seattle Sheraton Metropolitan Ballroom Foyer


Wednesday, October 08 | 3:30PM - 4:00PM
Coffee Break
Room: Westin Hotel Ballroom Foyer


Wednesday, October 08 | 4:00PM - 5:00PM
Grand Challenges & Keystone Symposia Joint Scientific Sessio
n: Innovation Panel Plenary
Room: Seattle Westin

* Sue Desmond-Hellman, CEO of the Bill & Melinda Gates Foundation

- Francis Collins, Director, National Institutes of Health
- Bill Gates, Co-Chair of the Bill & Melinda Gates Foundation

- Arunachalam Muruganantham, Founder of Jayaashree Industries

- Amy Smith, Founder and Co-Director, D-Lab, Massachusetts Institute of Technology


Wednesday, October 08 | 5:00PM - 6:30PM
Grand Challenges & Keystone Symposia: Joint Reception
Room: Seattle Westin


Thursday, October 09 | 7:30AM - 8:30AM
Breakfast
Room: Metropolitan Ballroom


Thursday, October 09 | 8:30AM - 11:30AM
Cell Death and Nucleic Acids as Adjuvants
Room: Metropolitan Ballroom
To understand how nucleic acids and other components of the host act as immunological adjuvants.
Speaker 1 of 6
* Emilio Flano, Seres Therapeutics, USA

Thursday, October 09 | 8:30AM - 11:30AM
Cell Death and Nucleic Acids as Adjuvants
Room: Metropolitan Ballroom
To understand how nucleic acids and other components of the host act as immunological adjuvants.
Speaker 2 of 6
Michael Gale, Jr., University of Washington, USA
Targeting RIG-I for Vaccine Adjuvant Activity

Thursday, October 09 | 8:30AM - 11:30AM
Cell Death and Nucleic Acids as Adjuvants
Room: Metropolitan Ballroom
To understand how nucleic acids and other components of the host act as immunological adjuvants.
Speaker 3 of 6
Ken J. Ishii, National Institute of Biomedical Innovation, Health and Nutrition, Japan
Nucleic Acids as 'Built-in' or 'Inducible' Adjuvant during Vaccination

Thursday, October 09 | 8:30AM - 11:30AM
Cell Death and Nucleic Acids as Adjuvants
Room: Metropolitan Ballroom
To understand how nucleic acids and other components of the host act as immunological adjuvants.
Speaker 4 of 6
Anna Marie Pyle, Yale University, USA
Small RIG-I Ligands and their Development as Antivirals and Vaccine Adjuvants

Thursday, October 09 | 8:30AM - 11:30AM
Cell Death and Nucleic Acids as Adjuvants
Room: Metropolitan Ballroom
To understand how nucleic acids and other components of the host act as immunological adjuvants.
Speaker 5 of 6
Thomas W. Dubensky, Jr., Tempest Therapeutics, USA
Development of Human STING-Activating Synthetic Cyclic Dinucleotide Derivatives as Adjuvants for Cancer Immunotherapy and Infectious Disease

Thursday, October 09 | 8:30AM - 11:30AM
Cell Death and Nucleic Acids as Adjuvants
Room: Metropolitan Ballroom
To understand how nucleic acids and other components of the host act as immunological adjuvants.
Speaker 6 of 6
Robert E. Johnston, Global Vaccines, Inc., USA
Short Talk: Biological Adjuvant Activity of Alphavirus Replicon Particles

Thursday, October 09 | 9:50AM - 10:10AM
Coffee Break
Room: Metropolitan Ballroom Foyer


Thursday, October 09 | 11:30AM - 1:00PM
Poster Setup
Room: Metropolitan Ballroom


Thursday, October 09 | 11:30AM - 2:30PM
On Own for Lunch


Thursday, October 09 | 1:00PM - 10:00PM
Poster Viewing
Room: Metropolitan Ballroom


Thursday, October 09 | 2:30PM - 4:30PM
Workshop 1: TLRs and STING
Room: Metropolitan Ballroom A

Speaker 1 of 8
* Robert R. Kane, Baylor University, USA
Synthesis and Protein Conjugation of TLR Agonists

Thursday, October 09 | 2:30PM - 4:30PM
Workshop 1: TLRs and STING
Room: Metropolitan Ballroom A

Speaker 2 of 8
Aideen C. Allen, Institut de Pharmacologie et de Biologie Structurale, France
A Novel TLR2 Agonist from B. pertussis Is a more Effective Adjuvant than Alum for an Acellular Pertussis Vaccine

Thursday, October 09 | 2:30PM - 4:30PM
Workshop 1: TLRs and STING
Room: Metropolitan Ballroom A

Speaker 3 of 8
Roger H. Brookes, Sanofi Pasteur, Canada
Dose-Ranging Analysis of H4 TB Vaccine Formulations in Mouse and Fresh Human
Whole Blood Reveal that an Excess of IC31® Adjuvant Is Needed for Immunomodulation


Thursday, October 09 | 2:30PM - 4:30PM
Workshop 1: TLRs and STING
Room: Metropolitan Ballroom A

Speaker 4 of 8
Mark T. Orr, Infectious Disease Research Institute, USA
Mechanistic Insights Into the TH1 Induction Capacity of Formulated TLR4 Agonist Adjuvants

Thursday, October 09 | 2:30PM - 4:30PM
Workshop 1: TLRs and STING
Room: Metropolitan Ballroom A

Speaker 5 of 8
Caroline Junqueira, Centro de Pesquisas René Rachou/ Fiocruz, Brazil
Attenuated Trypanosoma cruzi Expressing Tumor Antigen to Induce a Potent Antitumor Immunity Mediated by TLRs Agonists

Thursday, October 09 | 2:30PM - 4:30PM
Workshop 1: TLRs and STING
Room: Metropolitan Ballroom A

Speaker 6 of 8
Andres Sanchez Alberti, Universidad de Buenos Aires - CONICET, Argentina
Sting Agonist and Antigen Design as a Vaccine Model to Combat Parasitic Chronic Infections

Thursday, October 09 | 2:30PM - 4:30PM
Workshop 1: TLRs and STING
Room: Metropolitan Ballroom A

Speaker 7 of 8
* Yueh-Ming Loo, AstraZeneca, USA
Small Molecule RIG-I Agonists as Vaccine Adjuvants

Thursday, October 09 | 2:30PM - 4:30PM
Workshop 1: TLRs and STING
Room: Metropolitan Ballroom A

Speaker 8 of 8
Shan Lu, University of Massachusetts Medical Center, USA
Involvement of Aim2 Inflammasome Pathway in Antigen Specific Antibody Responses Elicited by HA-Expressing Influenza DNA Vaccine

Thursday, October 09 | 2:30PM - 4:30PM
Workshop 2: T Cells
Room: Metropolitan Ballroom B

Speaker 1 of 7
* Nancy A. Hosken, University of Washington, USA

Thursday, October 09 | 2:30PM - 4:30PM
Workshop 2: T Cells
Room: Metropolitan Ballroom B

Speaker 2 of 7
Alicja Misiak, Trinity College Dublin, Ireland
Lung gammadelta T Cells Mount Innate and Adaptive Immune Responses to Bordetella pertussis – Implications for Pertussis Vaccines

Thursday, October 09 | 2:30PM - 4:30PM
Workshop 2: T Cells
Room: Metropolitan Ballroom B

Speaker 3 of 7
Chiung-Yu Hung, University of Texas at San Antonio, USA
Th17 Immunity is Essential for Optimal Protection Against Coccidioides Infection

Thursday, October 09 | 2:30PM - 4:30PM
Workshop 2: T Cells
Room: Metropolitan Ballroom B

Speaker 4 of 7
* Stephen M. Carpenter, Regeneron Pharmaceuticals, USA
Heavily-Armed but Outnumbered: A Selective Loss of Memory CD8+ T Cells during Tuberculosis may Eclipse the Benefit of Vaccination

Thursday, October 09 | 2:30PM - 4:30PM
Workshop 2: T Cells
Room: Metropolitan Ballroom B

Speaker 5 of 7
Dipendra Kumar Mitra, All India Institute of Medical Sciences - AIIMS, India
Programed Death Receptor-1 Preferentially Inhibits Poly-Functional T Cells in Human Tuberculosis

Thursday, October 09 | 2:30PM - 4:30PM
Workshop 2: T Cells
Room: Metropolitan Ballroom B

Speaker 6 of 7
Yasser A. Aldhamen, Michigan State University, USA
Therapeutic Blockade of CRACC, a Novel Immune Modulation Strategy for Enhancing Memory T Cell Immune Responses

Thursday, October 09 | 2:30PM - 4:30PM
Workshop 2: T Cells
Room: Metropolitan Ballroom B

Speaker 7 of 7
Robert Weinkove, Capital & Coast District Health Board, New Zealand
Glycolipid-Peptide Conjugates Exploit Natural Killer T Cells to Enhance Peptide-Specific CD8+ T Cell Responses

Thursday, October 09 | 4:30PM - 5:00PM
Coffee Available
Room: Metropolitan Ballroom Foyer


Thursday, October 09 | 5:00PM - 7:00PM
The Action of Adjuvants on Dendritic Cell Subsets
Room: Metropolitan Ballroom
To learn about the use of adjuvants, alone, or in combination with biologicals, in cancer vaccines.
Speaker 1 of 4
* Jonathan A. Deane, Kumquat Biosciences, USA

Thursday, October 09 | 5:00PM - 7:00PM
The Action of Adjuvants on Dendritic Cell Subsets
Room: Metropolitan Ballroom
To learn about the use of adjuvants, alone, or in combination with biologicals, in cancer vaccines.
Speaker 2 of 4
Ofer Levy, Boston Children's Hospital, USA
In vitro Modeling to Inform Age-Specific Adjuvanted Vaccine Development

Thursday, October 09 | 5:00PM - 7:00PM
The Action of Adjuvants on Dendritic Cell Subsets
Room: Metropolitan Ballroom
To learn about the use of adjuvants, alone, or in combination with biologicals, in cancer vaccines.
Speaker 3 of 4
Claudia Jakubzick, Dartmouth College, USA
Short Talk: Dendritic Cell Subsets Require cis-Activation for Cytotoxic CD8 T Cell Induction

Thursday, October 09 | 5:00PM - 7:00PM
The Action of Adjuvants on Dendritic Cell Subsets
Room: Metropolitan Ballroom
To learn about the use of adjuvants, alone, or in combination with biologicals, in cancer vaccines.
Speaker 4 of 4
Karin Loré, Karolinska Institutet, Sweden
Innate Immune Activation in vivo after Adjuvant Administration

Thursday, October 09 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Metropolitan Ballroom


Thursday, October 09 | 7:30PM - 10:00PM
Poster Session 1
Room: Metropolitan Ballroom


Friday, October 10 | 7:30AM - 8:30AM
Breakfast
Room: Metropolitan Ballroom


Friday, October 10 | 8:30AM - 11:45AM
Immunostimulatory Properties of Particles
Room: Metropolitan Ballroom
Particles have long been known to have immunostimulatory properties. This session will discuss the mechanisms by which particles have this effect.
Speaker 1 of 7
* Rima L. McLeod, University of Illinois, USA

Friday, October 10 | 8:30AM - 11:45AM
Immunostimulatory Properties of Particles
Room: Metropolitan Ballroom
Particles have long been known to have immunostimulatory properties. This session will discuss the mechanisms by which particles have this effect.
Speaker 2 of 7
Tarek M. Fahmy, Yale University, USA
Modular Nanomaterials Orchestrating the Direction and Magnitude of the Immune Response

Friday, October 10 | 8:30AM - 11:45AM
Immunostimulatory Properties of Particles
Room: Metropolitan Ballroom
Particles have long been known to have immunostimulatory properties. This session will discuss the mechanisms by which particles have this effect.
Speaker 3 of 7
Gary J. Nabel, Sanofi, USA
Synthetic Nanoparticle and Virus-Like Particle Vaccines for Influenza and Alphaviruses: Developing New Technologies to Address Growing Public Health Concerns

Friday, October 10 | 8:30AM - 11:45AM
Immunostimulatory Properties of Particles
Room: Metropolitan Ballroom
Particles have long been known to have immunostimulatory properties. This session will discuss the mechanisms by which particles have this effect.
Speaker 4 of 7
James I. Andorko, University of Maryland, USA
Short Talk: Intrinsic Immunogenicity of Rapidly Degradable Polycations: Role of Physicochemical Properties

Friday, October 10 | 8:30AM - 11:45AM
Immunostimulatory Properties of Particles
Room: Metropolitan Ballroom
Particles have long been known to have immunostimulatory properties. This session will discuss the mechanisms by which particles have this effect.
Speaker 5 of 7
Marcela Rincon-Restrepo, École Polytechnique Fédérale de Lausanne, Switzerland
Short Talk: Polymersomes Enhance the Induction of Follicular Helper CD4 T Cells and Promote Long Antibody Responses

Friday, October 10 | 8:30AM - 11:45AM
Immunostimulatory Properties of Particles
Room: Metropolitan Ballroom
Particles have long been known to have immunostimulatory properties. This session will discuss the mechanisms by which particles have this effect.
Speaker 6 of 7
Darrell J. Irvine, Massachusetts Institute of Technology, USA
Controlling Immunization Potency and Safety through Molecular Targeting of Vaccines to Lymph Nodes

Friday, October 10 | 8:30AM - 11:45AM
Immunostimulatory Properties of Particles
Room: Metropolitan Ballroom
Particles have long been known to have immunostimulatory properties. This session will discuss the mechanisms by which particles have this effect.
Speaker 7 of 7
Steven Reed, Infectious Disease Research Institute, USA
Status and Clinical Development of Next Generation of TLR 4 Based Adjuvants

Friday, October 10 | 9:50AM - 10:10AM
Coffee Break
Room: Metropolitan Ballroom Foyer


Friday, October 10 | 11:45AM - 1:00PM
Poster Setup
Room: Metropolitan Ballroom


Friday, October 10 | 11:45AM - 2:30PM
On Own for Lunch


Friday, October 10 | 1:00PM - 10:00PM
Poster Viewing
Room: Metropolitan Ballroom


Friday, October 10 | 2:30PM - 4:30PM
Workshop on Adjuvant Formulation
Room: Metropolitan Ballroom A
Session to cover three case studies on adjuvant formulation. Co-sponsored by the Global HIV Vaccine Enterprise, the Bill &Melinda Gates Foundation and the Division of AIDS, National Institute of Allergy Infectious Diseases, National Institutes of Health.

Friday, October 10 | 4:30PM - 5:00PM
Coffee Available
Room: Metropolitan Ballroom Foyer


Friday, October 10 | 5:00PM - 7:00PM
Lipids, Emulsions and Detergents
Room: Metropolitan Ballroom
To understand the ways in which these unexpected materials improve immune responses.
Speaker 1 of 5
* Christopher B. Fox, Infectious Disease Research Institute, USA

Friday, October 10 | 5:00PM - 7:00PM
Lipids, Emulsions and Detergents
Room: Metropolitan Ballroom
To understand the ways in which these unexpected materials improve immune responses.
Speaker 2 of 5
Yan Shi, University of Calgary, Canada
Redirecting MHC Class II Antigen for MHC Class I Crosspresentation during Phagocytosis

Friday, October 10 | 5:00PM - 7:00PM
Lipids, Emulsions and Detergents
Room: Metropolitan Ballroom
To understand the ways in which these unexpected materials improve immune responses.
Speaker 3 of 5
Anja Seubert, GlaxoSmithKline, Italy
The Mechanism of Action of the Oil-in-Water Adjuvant MF59

Friday, October 10 | 5:00PM - 7:00PM
Lipids, Emulsions and Detergents
Room: Metropolitan Ballroom
To understand the ways in which these unexpected materials improve immune responses.
Speaker 4 of 5
Eugene Maraskovsky, CSL Limited, Australia
Mechanism of Action for Induction of Innate and Adaptive Immune Responses using ISCOMATRIX® Adjuvant

Friday, October 10 | 5:00PM - 7:00PM
Lipids, Emulsions and Detergents
Room: Metropolitan Ballroom
To understand the ways in which these unexpected materials improve immune responses.
Speaker 5 of 5
Anthony L. Desbien, Aduro Biotech, USA
Short Talk: A Role for the Inflammasome during Immunization with the TLR4 Agonist GLA when Combined with a Squalene Emulsion

Friday, October 10 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Metropolitan Ballroom


Friday, October 10 | 7:30PM - 10:00PM
Poster Session 2
Room: Metropolitan Ballroom


Saturday, October 11 | 7:30AM - 8:30AM
Breakfast
Room: Metropolitan Ballroom


Saturday, October 11 | 8:30AM - 11:30AM
Human Genetics and Adjuvants
Room: Metropolitan Ballroom
The genetic make up of individuals affects their reponses to vaccines. This issue will be discussed here.
Speaker 1 of 6
* Angelika Riemer, German Cancer Research Center /DKFZ, Germany

Saturday, October 11 | 8:30AM - 11:30AM
Human Genetics and Adjuvants
Room: Metropolitan Ballroom
The genetic make up of individuals affects their reponses to vaccines. This issue will be discussed here.
Speaker 2 of 6
Jean-Laurent Casanova, Rockefeller University, USA
Toward a Genetic Theory of Childhood Infectious Diseases

Saturday, October 11 | 8:30AM - 11:30AM
Human Genetics and Adjuvants
Room: Metropolitan Ballroom
The genetic make up of individuals affects their reponses to vaccines. This issue will be discussed here.
Speaker 3 of 6
Rafick Sekaly, Emory University, USA
Predictors of Adjuvant and Vaccine Efficacy

Saturday, October 11 | 8:30AM - 11:30AM
Human Genetics and Adjuvants
Room: Metropolitan Ballroom
The genetic make up of individuals affects their reponses to vaccines. This issue will be discussed here.
Speaker 4 of 6
Emmanuel Mignot, Stanford University School of Medicine, USA
Narcolepsy, Vaccination and Immunogenetics

Saturday, October 11 | 8:30AM - 11:30AM
Human Genetics and Adjuvants
Room: Metropolitan Ballroom
The genetic make up of individuals affects their reponses to vaccines. This issue will be discussed here.
Speaker 5 of 6
Robert L. Coffman, Dynavax Technologies, USA
Systems Biology Analysis of the Human Response to Hepatitis B Vaccines using Alum or CpG Oligonucleotide Adjuvants

Saturday, October 11 | 8:30AM - 11:30AM
Human Genetics and Adjuvants
Room: Metropolitan Ballroom
The genetic make up of individuals affects their reponses to vaccines. This issue will be discussed here.
Speaker 6 of 6
Taiki Aoshi, National Institute of Biomedical Innovation, Japan
Short Talk: Adjuvant Database Project: Comprehensive Transcriptome Analysis in Animal Models

Saturday, October 11 | 9:50AM - 10:10AM
Coffee Break
Room: Metropolitan Ballroom Foyer


Saturday, October 11 | 11:30AM - 1:00PM
Poster Setup
Room: Metropolitan Ballroom


Saturday, October 11 | 11:30AM - 2:30PM
On Own for Lunch


Saturday, October 11 | 1:00PM - 10:00PM
Poster Viewing
Room: Metropolitan Ballroom


Saturday, October 11 | 2:30PM - 4:30PM
Workshop 3: VLPs and Antigen Presentation
Room: Metropolitan Ballroom A

Speaker 1 of 8
* Darrell J. Irvine, Massachusetts Institute of Technology, USA

Saturday, October 11 | 2:30PM - 4:30PM
Workshop 3: VLPs and Antigen Presentation
Room: Metropolitan Ballroom A

Speaker 2 of 8
Rajesh Kumar, Tulane University, USA
Plasmodium falciparum Pfs25 Produced in E. coli Delivered with Various Nanoparticles Exhibit Strong Malaria Transmission Blocking Immunity

Saturday, October 11 | 2:30PM - 4:30PM
Workshop 3: VLPs and Antigen Presentation
Room: Metropolitan Ballroom A

Speaker 3 of 8
Masayuki Hayashi, Mitsubishi Tanabe Pharma, Japan
AdvaxTM, a Formulation of Delta Inulin Microparticles, Is a Non-Canonical Adjuvant that Induces Distinct Immune Response Depending on the Property of Vaccine Antigen

Saturday, October 11 | 2:30PM - 4:30PM
Workshop 3: VLPs and Antigen Presentation
Room: Metropolitan Ballroom A

Speaker 4 of 8
Karen Martins, USAMRIID, USA
Impact of Adjuvants on VLP-Mediated Protection from Ebola Virus Challenge

Saturday, October 11 | 2:30PM - 4:30PM
Workshop 3: VLPs and Antigen Presentation
Room: Metropolitan Ballroom A

Speaker 5 of 8
Marie-Ève Lebel, INRS, Institut Armand Frappier Research Centre, Canada
Plant Virus-Like Nanoparticles as Adjuvant: Mechanisms of Action and Application for Cancer Immunotherapy

Saturday, October 11 | 2:30PM - 4:30PM
Workshop 3: VLPs and Antigen Presentation
Room: Metropolitan Ballroom A

Speaker 6 of 8
Gokul Swaminathan, Merck Research Laboratories Cambridge Exploratory Science Center, USA
A Novel Cationic Lipid Nanoparticle Adjuvant Significantly Enhances B Cell and T Cell Responses to Recombinant Sub-Unit Viral Vaccines

Saturday, October 11 | 2:30PM - 4:30PM
Workshop 3: VLPs and Antigen Presentation
Room: Metropolitan Ballroom A

Speaker 7 of 8
Gervais Rioux, Université Laval, Canada
Effect of PapMV Adjuvant on the Immune Response Kinetic of Inactivated Flu Vaccine

Saturday, October 11 | 2:30PM - 4:30PM
Workshop 3: VLPs and Antigen Presentation
Room: Metropolitan Ballroom A

Speaker 8 of 8
* Elizabeth A. Leadbetter, University of Texas Long School of Medicine, USA
Glycolipid Adjuvant-Containing Nanoparticles Protect Against Streptococcus Pneumoniae

Saturday, October 11 | 2:30PM - 4:30PM
Workshop 4: Adjuvant Profiling
Room: Metropolitan Ballroom B

Speaker 1 of 7
* Mario Barro, Sanofi Pasteur, USA
Adjuvants for Novel and More Efficacious Influenza Vaccines

Saturday, October 11 | 2:30PM - 4:30PM
Workshop 4: Adjuvant Profiling
Room: Metropolitan Ballroom B

Speaker 2 of 7
Christopher B. Fox, Infectious Disease Research Institute, USA
Benefits and Limitations of in vitro Human Whole Blood and Macrophage Cell Line Assays to Evaluate Activity of Adjuvant Formulations

Saturday, October 11 | 2:30PM - 4:30PM
Workshop 4: Adjuvant Profiling
Room: Metropolitan Ballroom B

Speaker 3 of 7
Wivine Burny, GlaxoSmithKline, Belgium
Associations between Reactogenicity Symptoms and Parameters of the Early Immune Response to Adjuvanted Vaccines in Humans

Saturday, October 11 | 2:30PM - 4:30PM
Workshop 4: Adjuvant Profiling
Room: Metropolitan Ballroom B

Speaker 4 of 7
Takuo Mizukami, National Institute of Infectious Diseases, Japan
System Vaccinology Enables to Evaluate the Safety of the Influenza Vaccine and the Adjuvant with a Multiplex Gene Detection System of Novel Biomarkers in the Pre-Clinical Study and Lot Release Test

Saturday, October 11 | 2:30PM - 4:30PM
Workshop 4: Adjuvant Profiling
Room: Metropolitan Ballroom B

Speaker 5 of 7
Jourdan K. Posner, University of Hawaii, Manoa, USA
The Effect of Possible Vaccine Adjuvants on the Differentiation and Activation of B Cell Subsets Important to the Germinal Center Reaction

Saturday, October 11 | 2:30PM - 4:30PM
Workshop 4: Adjuvant Profiling
Room: Metropolitan Ballroom B

Speaker 6 of 7
Katy M. Graef, BIO Ventures for Global Health, USA
Accelerating Vaccine Development through Cross-Sector Collaborations

Saturday, October 11 | 2:30PM - 4:30PM
Workshop 4: Adjuvant Profiling
Room: Metropolitan Ballroom B

Speaker 7 of 7
Emily Field, Loyola University Chicago, USA
Developing Adenovirus-Vector Vaccines for MRSA

Saturday, October 11 | 4:30PM - 5:00PM
Coffee Available
Room: Metropolitan Ballroom Foyer


Saturday, October 11 | 5:00PM - 7:00PM
Guiding the Immune Response
Room: Metropolitan Ballroom
Different adjuvants generate different types of immune response. The means by which they do this will be discussed here.
Speaker 1 of 5
* Martha A. Alexander-Miller, Wake Forest University School of Medicine, USA

Saturday, October 11 | 5:00PM - 7:00PM
Guiding the Immune Response
Room: Metropolitan Ballroom
Different adjuvants generate different types of immune response. The means by which they do this will be discussed here.
Speaker 2 of 5
Kingston H.G. Mills, Trinity Biomedical Sciences Institute (TBSI), Ireland
TLR-Based Adjuvants for Infectious Disease and Cancer Vaccines - Enhancing Effector Over Regulatory T Cell Responses

Saturday, October 11 | 5:00PM - 7:00PM
Guiding the Immune Response
Room: Metropolitan Ballroom
Different adjuvants generate different types of immune response. The means by which they do this will be discussed here.
Speaker 3 of 5
Ross M. Kedl, University of Colorado Denver, USA
T Cell Vaccinology: Lessons Learned in Primates

Saturday, October 11 | 5:00PM - 7:00PM
Guiding the Immune Response
Room: Metropolitan Ballroom
Different adjuvants generate different types of immune response. The means by which they do this will be discussed here.
Speaker 4 of 5
Philippa C. Marrack, HHMI/National Jewish Health, USA
Host DNA Acts as an Adjuvant in Unexpected Situations

Saturday, October 11 | 5:00PM - 7:00PM
Guiding the Immune Response
Room: Metropolitan Ballroom
Different adjuvants generate different types of immune response. The means by which they do this will be discussed here.
Speaker 5 of 5
Michael Y. Gerner, NIAID, National Institutes of Health, USA
Short Talk: Strategically Localized Lymph-Sampling Dendritic Cells Promote Rapid T Cell Responses to Particulate Vaccines and Lymph-Borne Pathogens

Saturday, October 11 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Metropolitan Ballroom


Saturday, October 11 | 7:30PM - 10:00PM
Poster Session 3
Room: Metropolitan Ballroom


Sunday, October 12 | 7:30AM - 8:30AM
Breakfast
Room: Metropolitan Ballroom


Sunday, October 12 | 8:30AM - 12:30PM
Adjuvants for Still Unmet Needs
Room: Metropolitan Ballroom
Here we will discuss the use of old and new adjuvants in new vaccines.
Speaker 1 of 8
* Susan Baldwin, Infectious Disease Research Institute, USA

Sunday, October 12 | 8:30AM - 12:30PM
Adjuvants for Still Unmet Needs
Room: Metropolitan Ballroom
Here we will discuss the use of old and new adjuvants in new vaccines.
Speaker 2 of 8
Bali Pulendran, Stanford University School of Medicine, USA
Systems Vaccinology: Enabling Rational Vaccine Design with Systems Biology


Sunday, October 12 | 8:30AM - 12:30PM
Adjuvants for Still Unmet Needs
Room: Metropolitan Ballroom
Here we will discuss the use of old and new adjuvants in new vaccines.
Speaker 3 of 8
Lawrence Corey, Fred Hutchinson Cancer Research Center, USA
Concepts in the Immunotherapy of HSV 2 Infections Role of Adjuvants

Sunday, October 12 | 8:30AM - 12:30PM
Adjuvants for Still Unmet Needs
Room: Metropolitan Ballroom
Here we will discuss the use of old and new adjuvants in new vaccines.
Speaker 4 of 8
Nathalie Garçon, Bioaster, France
Adjuvants for Vaccines against the Big 3: An Historical Perspective

Sunday, October 12 | 8:30AM - 12:30PM
Adjuvants for Still Unmet Needs
Room: Metropolitan Ballroom
Here we will discuss the use of old and new adjuvants in new vaccines.
Speaker 5 of 8
Peter L. Andersen, Statens Serum Institut, Denmark
Tailoring Adjuvants for Tuberculosis Vaccines

Sunday, October 12 | 8:30AM - 12:30PM
Adjuvants for Still Unmet Needs
Room: Metropolitan Ballroom
Here we will discuss the use of old and new adjuvants in new vaccines.
Speaker 6 of 8
Derek T. O'Hagan, GlaxoSmithKline Vaccines, USA
Can We Design a Single Delivery System for a Broad Range of Molecules from Small Molecule Adjuvants, to Proteins and RNA Vaccines?

Sunday, October 12 | 8:30AM - 12:30PM
Adjuvants for Still Unmet Needs
Room: Metropolitan Ballroom
Here we will discuss the use of old and new adjuvants in new vaccines.
Speaker 7 of 8
Nitasha R. Bennett, University of Wisconsin, Madison, USA
Short Talk: Triggering B and T Cell Activation with Synthetic Multivalent Antigens

Sunday, October 12 | 8:30AM - 12:30PM
Adjuvants for Still Unmet Needs
Room: Metropolitan Ballroom
Here we will discuss the use of old and new adjuvants in new vaccines.
Speaker 8 of 8
Michael Fichter, University Medical Center Mainz, Germany
Short Talk: Yeast-Based Expression and Purification of Recombinant Hepatitis C Virus Proteins for the Development of Novel Polymeric Protein Nanovaccines

Sunday, October 12 | 9:50AM - 10:10AM
Coffee Break
Room: Metropolitan Ballroom Foyer


Sunday, October 12 | 11:45AM - 2:30PM
On Own for Lunch


Sunday, October 12 | 2:30PM - 4:30PM
Workshop 5: Vaccine Mechanisms and Formulations
Room: Metropolitan Ballroom A

Speaker 1 of 7
* Christopher Jewell, University of Maryland, USA

Sunday, October 12 | 2:30PM - 4:30PM
Workshop 5: Vaccine Mechanisms and Formulations
Room: Metropolitan Ballroom A

Speaker 2 of 7
Hongming Hu, Providence Cancer Center, USA
TLR and NALP3 Inflammasome Dependent Innate Immune Responses to Tumor-Derived Autohagosomes (DRibbles)

Sunday, October 12 | 2:30PM - 4:30PM
Workshop 5: Vaccine Mechanisms and Formulations
Room: Metropolitan Ballroom A

Speaker 3 of 7
Daniel Villarreal, Advaxis, USA
Immunoadjuvant IL-33 Amplifies Memory CD8 T Cells and Enhances Antigen-Specific Tumor and Viral Immunity

Sunday, October 12 | 2:30PM - 4:30PM
Workshop 5: Vaccine Mechanisms and Formulations
Room: Metropolitan Ballroom A

Speaker 4 of 7
* Arnaud Didierlaurent, University of Geneva, Switzerland
Early NK Cell Activation as a Result of MPL and QS-21 Combination Controls the Adjuvant effect Induced by the Human Adjuvant System AS01

Sunday, October 12 | 2:30PM - 4:30PM
Workshop 5: Vaccine Mechanisms and Formulations
Room: Metropolitan Ballroom A

Speaker 5 of 7
Iain David Welsby, Université Libre de Bruxelles, Belgium
Understanding the Cellular and Molecular Mechanisms Involved in the Adjuvanticity of a Liposomal QS-21 Formulation

Sunday, October 12 | 2:30PM - 4:30PM
Workshop 5: Vaccine Mechanisms and Formulations
Room: Metropolitan Ballroom A

Speaker 6 of 7
Charlotte Givord, Université Libre de Bruxelles, Belgium
Deciphering the Signaling Pathways Involved in the Immunostimulatory Properties of the Adjuvant System AS03

Sunday, October 12 | 2:30PM - 4:30PM
Workshop 5: Vaccine Mechanisms and Formulations
Room: Metropolitan Ballroom A

Speaker 7 of 7
Amy Galliher-Beckley, MFB Fertility, USA
Novel Low-Cost, Easy-to-Use Emulsion Is a Stable Adjuvant and Induces Long-Lasting Antibody Responses to Swine Influenza Virus and Mycoplasma hyopneumoniae

Sunday, October 12 | 2:30PM - 4:30PM
Workshop 6: Role of Dendritic Cells in vivo and Dendritic Ce
ll Targeting
Room: Metropolitan Ballroom B

Speaker 1 of 9
* Ross M. Kedl, University of Colorado Denver, USA

Sunday, October 12 | 2:30PM - 4:30PM
Workshop 6: Role of Dendritic Cells in vivo and Dendritic Ce
ll Targeting
Room: Metropolitan Ballroom B

Speaker 2 of 9
* Richard A. Kroczek, Robert Koch-Institute, Germany
Targeting of Antigen into XCR1+ Dendritic Cells Combined with a Non-Viral Boost Regime Induces Massive CD8+ T Cell Cytotoxicity Capable of Controlling 50xLD50 Listeria Infection and Eradicating Established Tumors

Sunday, October 12 | 2:30PM - 4:30PM
Workshop 6: Role of Dendritic Cells in vivo and Dendritic Ce
ll Targeting
Room: Metropolitan Ballroom B

Speaker 3 of 9
Monica Montes, Baylor Institute for Immunology Research, USA
Anti-Human CD40 Antibodies with Selective Functional Properties

Sunday, October 12 | 2:30PM - 4:30PM
Workshop 6: Role of Dendritic Cells in vivo and Dendritic Ce
ll Targeting
Room: Metropolitan Ballroom B

Speaker 4 of 9
Rossella Cioncada, University of Siena, Italy
Vaccine Adjuvant MF59 Promotes in vivo Differentiation of Monocyte-Derived Dendritic Cells within Medullary Compartment of the Draining Lymph Nodes, which Correlates with Increased Ability to Trigger T Cell Response

Sunday, October 12 | 2:30PM - 4:30PM
Workshop 6: Role of Dendritic Cells in vivo and Dendritic Ce
ll Targeting
Room: Metropolitan Ballroom B

Speaker 5 of 9
Stefaan De Koker, University of Gent, Belgium
Inflammatory DCs Constitute a Crucial Source of IL-12 but Fail to Present Antigen in Case of CpG-Adjuvanted Vaccines

Sunday, October 12 | 2:30PM - 4:30PM
Workshop 6: Role of Dendritic Cells in vivo and Dendritic Ce
ll Targeting
Room: Metropolitan Ballroom B

Speaker 6 of 9
Laura E. Noges, Fred Hutchinson Cancer Research Center, USA
Host DNA Plays a Role in Generating CD4 T Cell Responses to Various Vaccine Adjuvants

Sunday, October 12 | 2:30PM - 4:30PM
Workshop 6: Role of Dendritic Cells in vivo and Dendritic Ce
ll Targeting
Room: Metropolitan Ballroom B

Speaker 7 of 9
Elizabeth A. Thompson, Karolinska Institute, Sweden
Intravenous Administration of an Agonistic CD40 Antibody Induces Strong T Cell Responses in the Lung

Sunday, October 12 | 2:30PM - 4:30PM
Workshop 6: Role of Dendritic Cells in vivo and Dendritic Ce
ll Targeting
Room: Metropolitan Ballroom B

Speaker 8 of 9
Chinnaswamy Jagannath, Houston Methodist Research Institute, USA
Induction of Autophagy as an Emerging Molecular Mechanism of Immunoadjvants

Sunday, October 12 | 2:30PM - 4:30PM
Workshop 6: Role of Dendritic Cells in vivo and Dendritic Ce
ll Targeting
Room: Metropolitan Ballroom B

Speaker 9 of 9
Frédéric Martinon, INSERM U1184 Commissariat Energie Atomique (CEA) - Université Paris-Saclay, France
TLR Ligands Indirectly Activate Skin Langerhans Cells by Triggering Local Recruitment of Inflammatory Cells

Sunday, October 12 | 2:30PM - 4:30PM
Workshop 7: Vaccine Delivery
Room: Ravenna

Speaker 1 of 6
Tarek Hamouda, NanoBio Corp., USA
Intranasal Nanoemulsion-Adjuvanted Genital Herpes Vaccine; A New Approach Utilizing Mucosal Immunity to Induce Protection Against HSV2 Infections

Sunday, October 12 | 2:30PM - 4:30PM
Workshop 7: Vaccine Delivery
Room: Ravenna

Speaker 2 of 6
* Olivia M. Flynn, University College Cork, Ireland
Immunogenicity of dmLT Adjuvanted Vaccines in ImmuPatch Dissolvable Microneedle Patches in Mice

Sunday, October 12 | 2:30PM - 4:30PM
Workshop 7: Vaccine Delivery
Room: Ravenna

Speaker 3 of 6
Chintan Hareshbhai Kapadia, University of North Carolina at Chapel Hill, USA
PRINT Nanoparticulate Subunit Vaccine to Combat Cancer

Sunday, October 12 | 2:30PM - 4:30PM
Workshop 7: Vaccine Delivery
Room: Ravenna

Speaker 4 of 6
Sudhir Pai Kasturi, Emory University, USA
Programming the Magnitude and Persistence of Humoral Immunity Against HIV Using Novel TLR Ligands Delivered in Biodegradable Nanoparticles

Sunday, October 12 | 2:30PM - 4:30PM
Workshop 7: Vaccine Delivery
Room: Ravenna

Speaker 5 of 6
Kouji Kobiyama, National Institute of Biomedical Innovation, Japan
K3-SPG, a Nano-Particulate TLR9 Agonistic Ligand Works as a Potent IFN Inducer and CTL Adjuvant

Sunday, October 12 | 2:30PM - 4:30PM
Workshop 7: Vaccine Delivery
Room: Ravenna

Speaker 6 of 6
* Aaron Palmer Esser-Kahn, University of California, Irvine, USA
Controlling Adjuvant Activity with Light

Sunday, October 12 | 4:30PM - 5:00PM
Coffee Available
Room: Metropolitan Ballroom Foyer


Sunday, October 12 | 5:00PM - 6:30PM
New Approaches to Vaccines
Room: Metropolitan Ballroom

Speaker 1 of 3
* Laura Shackelton, Bill & Melinda Gates Foundation, USA

Sunday, October 12 | 5:00PM - 6:30PM
New Approaches to Vaccines
Room: Metropolitan Ballroom

Speaker 2 of 3
Jenny P.Y. Ting, University of North Carolina at Chapel Hill, USA
Impact of NLR Proteins on Innate and Adaptive Immunity

Sunday, October 12 | 5:00PM - 6:30PM
New Approaches to Vaccines
Room: Metropolitan Ballroom

Speaker 3 of 3
Robert A. Seder, NIAID, National Institutes of Health, USA
Adjuvants for HIV Vaccines, Mice versus Humans

Sunday, October 12 | 6:30PM - 7:00PM
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
Room: Metropolitan Ballroom


Sunday, October 12 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Metropolitan Ballroom


Sunday, October 12 | 8:00PM - 11:00PM
Entertainment
Room: Metropolitan Ballroom


Sunday, October 12 | 8:00PM - 11:00PM
Cash Bar
Room: Metropolitan Ballroom


Monday, October 13 | 10:25AM - 10:25AM
Departure


*Session Chair.